ライフサイエンスコーパス: bone marrow transplantation

1 , dermatologic conditions, or solid-organ or bone marrow transplantation.

2 sident beds that could not be transferred by bone marrow transplantation.

3 prevention of GVHD in preclinical models of bone marrow transplantation.

4 ant in many clinical applications, including bone marrow transplantation.

5 erapeutic responses of an NPC2 patient after bone marrow transplantation.

6 oughout life and are the functional units of bone marrow transplantation.

7 duals with diarrhea after they had undergone bone marrow transplantation.

8 en gained adaptive immunity after undergoing bone marrow transplantation.

9 gimens to improve the safety and efficacy of bone marrow transplantation.

10 e repopulated to a normal level by syngeneic bone marrow transplantation.

11 is a critical complication after allogeneic bone marrow transplantation.

12 iTregs) for the induction of tolerance after bone marrow transplantation.

13 GVHD) is the main complication of allogeneic bone marrow transplantation.

14 sease following sex-mismatched HLA-identical bone marrow transplantation.

15 reconstitution of hematopoiesis upon serial bone marrow transplantation.

16 as partially reduced and then recovered upon bone marrow transplantation.

17 r restrict alloreactivity after experimental bone marrow transplantation.

18 lls were severely compromised in competitive bone marrow transplantation.

19 Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation.

20 ecific P2X(7)-deficient animals generated by bone marrow transplantation.

21 rrected the T cell lymphopenia in mice after bone marrow transplantation.

22 er remission, and requirement for allogeneic bone marrow transplantation.

23 scence protein transgenic mice were used for bone marrow transplantation.

24 n this patient, who had undergone successful bone marrow transplantation.

25 r T cells after allogeneic but not syngeneic bone marrow transplantation.

26 (GVHD) is a major complication of allogeneic bone marrow transplantation.

27 HC class I-restricted T-cell responses after bone marrow transplantation.

28 the conditioning regimen, and declined after bone marrow transplantation.

29 th lentivirus expressing Hmga2 and performed bone marrow transplantation.

30 only, both, or neither were generated using bone marrow transplantation.

31 cally relevant murine models of experimental bone marrow transplantation.

32 smatched) and fully MHC-mismatched models of bone marrow transplantation.

33 regenerative capacity of HSCs in competitive bone marrow transplantation.

34 ophic epidermolysis bullosa after allogeneic bone marrow transplantation.

35 ally applied in clinical conditions, such as bone marrow transplantation.

36 to treat graft-versus-host disease following bone marrow transplantation.

37 eased resistance to MRSA was transferable by bone marrow transplantation.

38 ythroid short-term radioprotection following bone marrow transplantation.

39 changes during stress hematopoiesis, such as bone marrow transplantation.

40 ibuted to atherogenesis in a murine model of bone marrow transplantation.

41 requiring lifelong transfusion or allogeneic bone marrow transplantation.

42 f malignant cells, the therapeutic intent of bone marrow transplantation.

43 g recovery of the hematopoietic system after bone marrow transplantation.

44 ymphopenias and hinder T cell recovery after bone marrow transplantation.

45 ve oxygen species (ROS) following allogeneic bone marrow transplantation.

46 , both in physiological conditions and after bone marrow transplantation.

47 itical role of donor sleep in the success of bone marrow transplantation.

48 ponses in leukemia patients after allogeneic bone marrow transplantation.

49 her models, including whole-body irradiation/bone-marrow transplantation.

50 stion of long-term HSC function along serial bone marrow transplantations.

51 iology was 47.2% (95% CI, 34.3-59.1) and for bone marrow transplantation 22.8% (95% CI, 8.7-40.8).

52 useful for HSPC collection before autologous bone marrow transplantation (ABMT).

53 (Tc1) or Tc17 cells combined with autologous bone marrow transplantation after total body irradiation

54 One child underwent bone marrow transplantation aged 9 months, with apparent

55 Allogeneic bone marrow transplantation (allo-BMT) is a curative the

56 s remains the major limitation of allogeneic bone marrow transplantation (allo-BMT).

57 (GVHD), a serious complication of allogeneic bone marrow transplantation (allo-BMT).

58 isease (GVHD) after myeloablative allogeneic bone marrow transplantation (alloBMT).

59 Bone marrow transplantation alone provided essentially n

60 th a STAT6 inhibitor and IL-4(-/-)IL-13(-/-) bone marrow transplantation also protected against Schis

61 Allogeneic bone marrow transplantation, although limited by donor a

62 in vivo, we generated CD36 chimeric mice by bone marrow transplantation and evaluated the two models

63 an engraftment and the acquired tolerance of bone marrow transplantation and eventually clarified the

64 scle injury model combined with irradiation, bone marrow transplantation and in vivo imaging, we show

65 The combination of bone marrow transplantation and local muscle radiation p

66 apeutic avenues, and some of them, including bone marrow transplantation and mesenchymal stem cell th

67 First, we performed adoptive bone marrow transplantation and observed that introducti

68 Bone marrow transplantation and platelet depletion/recon

69 Bone marrow transplantation and platelet transfusion stu

70 r human leukocyte antigen-matched kidney and bone marrow transplantation and the induction of mixed l

71 Mice chimeric for COX-2 were derived by bone marrow transplantation and underwent CLP.

72 mouse models of cancer, infectious disease, bone marrow transplantation, and autoimmune disease.

73 ents using pancreas-specific Perk knockouts, bone marrow transplantation, and cultured pancreatic isl

74 GvHD) is a common complication of allogeneic bone marrow transplantation, and has a major effect on t

75 be presented by the CD8(-) cDC subset after bone marrow transplantation, and inflammation during GVH

76 reatment, including chemotherapy, radiation, bone marrow transplantation, and newer modalities such a

77 also limits T lineage regeneration following bone marrow transplantation, and so contributes to the s

78 These data have implications for successful bone marrow transplantation, and suggest that tolerance

79 l irradiation, reconstitution with syngeneic bone marrow transplantation, and therapy with the immuno

80 ent of murine SGVHD, control and CsA-treated bone marrow transplantation animals were treated with br

81 Corticosteriod therapy and bone marrow transplantation are common treatment options

82 alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a concomitant

83 hieved in NOD mice receiving anti-CD154 with bone marrow transplantation as the means of tolerizing p

84 Bone marrow transplantation assays reveal that enhanced

85 a levels accelerates MLL-AF9-mediated AML in bone marrow transplantation assays.

86 logenous leukemia (AML) with long latency in bone marrow transplantation assays.

87 BO blood group mismatched solid organ and/or bone marrow transplantation between donor and recipient.

88 Reciprocal bone marrow transplantation between KitW/Wv and KitWsh/W

89 ostasis and thrombosis, we performed crossed bone marrow transplantations between C57BL/6J and Vwf(-/

90 in [ATG]) facilitates immune tolerance after bone marrow transplantation (BMT) across major histocomp

91 t donor-recipient immune tolerance following bone marrow transplantation (BMT) across MHC barriers vi

92 cause of late mortality following allogeneic bone marrow transplantation (BMT) and is characterized b

93 transplantation (VCA) with chimerism through bone marrow transplantation (BMT) are currently being pu

94 g hematopoietic stem cell transplantation or bone marrow transplantation (BMT) as therapy for various

95 Colony forming/replating and bone marrow transplantation (BMT) assays showed that Alo

96 ficantly improves survival (P < .0001) after bone marrow transplantation (BMT) by inhibiting the init

97 However, LT is not curative and only bone marrow transplantation (BMT) can correct the underl

98 Neonatal bone marrow transplantation (BMT) could offer a novel th

99 rineurial microenvironment using a series of bone marrow transplantation (BMT) experiments in transge

100 Bone marrow transplantation (BMT) for class 3 patients w

101 emia (ALL) persisting or relapsing following bone marrow transplantation (BMT) has a dismal prognosis

102 Indeed, bone marrow transplantation (BMT) has its genesis in rod

103 including alveolar macrophages (AMs), after bone marrow transplantation (BMT) have impaired host def

104 eir therapeutic potential following congenic bone marrow transplantation (BMT) in a proteoglycan-indu

105 hat inhibits KIT, enhances engraftment after bone marrow transplantation (BMT) in mice.

106 ed virus (AAV)2/5-mediated gene therapy with bone marrow transplantation (BMT) in the INCL mouse.

107 nd to host alloantigens following allogeneic bone marrow transplantation (BMT) induce graft-versus-ho

108 lignant hematological disorders, HLA-matched bone marrow transplantation (BMT) is curative.

109 curative potential of MHC-matched allogeneic bone marrow transplantation (BMT) is in part because of

110 Bone marrow transplantation (BMT) is often followed by a

111 T-cell regeneration after bone marrow transplantation (BMT) is often slow and inco

112 However, simultaneous kidney or VCA and bone marrow transplantation (BMT) is problematic because

113 Bone marrow transplantation (BMT) is the other therapeut

114 Here we show that bone marrow transplantation (BMT) of PARP-knockout (PARP

115 f pediatric obesity may significantly affect bone marrow transplantation (BMT) outcomes.

116 Bone marrow transplantation (BMT) performance can be lim

117 Because bone marrow transplantation (BMT) results in decreased c

118 in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflam

119 vere and frequent complication of allogeneic bone marrow transplantation (BMT) that involves the gast

120 cGVHD) is a major complication of allogeneic bone marrow transplantation (BMT) the immunopathogenesis

121 n DNA-PKcs(3A/3A) mutant mice, which require bone marrow transplantation (BMT) to prevent early morta

122 Chimeric mice were generated by bone marrow transplantation (BMT) using Cd39 null or wt

123 nt study, chimeric mice were created through bone marrow transplantation (BMT) using wild-type and CX

124 Haploidentical bone marrow transplantation (BMT) with 300 muCi (90)Y-an

125 recently achieved in the clinic by combining bone marrow transplantation (BMT) with kidney transplant

126 revents successful outcomes after allogeneic bone marrow transplantation (BMT), an effective therapy

127 the hematopoietic lineages to recover after bone marrow transplantation (BMT), but the reasons for t

128 is a major cause of mortality in allogeneic bone marrow transplantation (BMT), for which administrat

129 fe-threatening complication after allogeneic bone marrow transplantation (BMT), particularly in the p

130 Here we use bone marrow transplantation (BMT), total body irradiatio

131 Using murine models of bone marrow transplantation (BMT), we find that MHCII(-/

132 Using a syngeneic mouse model of bone marrow transplantation (BMT), we have previously de

133 In a mouse model of syngeneic bone marrow transplantation (BMT), we previously reporte

134 hogenesis of graft-versus-host disease after bone marrow transplantation (BMT).

135 anced hematopoietic reconstitution following bone marrow transplantation (BMT).

136 esents a major complication after allogeneic bone marrow transplantation (BMT).

137 raft-versus-leukemia (GVL) effects following bone marrow transplantation (BMT).

138 mune hepatitis (AIH) has been reported after bone marrow transplantation (BMT).

139 tivity represents a highly desirable goal in bone marrow transplantation (BMT).

140 opment in euthymic and athymic recipients of bone marrow transplantation (BMT).

141 2/5 (AAV2/5) gene therapy and myeloreductive bone marrow transplantation (BMT).

142 versus-host disease (aGvHD) after allogeneic bone marrow transplantation (BMT).

143 d a mouse MLIV model to test the efficacy of bone marrow transplantation (BMT).

144 ns a major complication following allogeneic bone marrow transplantation (BMT).

145 s-tumor [GVT]) in cancer patients undergoing bone marrow transplantation (BMT).

146 minish GVL, leading to greater relapse after bone marrow transplantation (BMT).

147 cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389).

148 rm-specific betaAR knockout (betaARKO) or WT bone-marrow transplantation (BMT) and after full reconst

149 Bone marrow transplantation (BMTx), kidney transplantati

150 invasive candidiasis in patients undergoing bone marrow transplantation but is not approved for use

151 lethal and morbid complication of allogeneic bone marrow transplantation, but GVHD is tightly linked

152 ocyte antigen-mismatched combined kidney and bone marrow transplantation (CKBMT).

153 Bone marrow transplantation combined with ACT of antitum

154 awa and Kabashima) address the issue whether bone marrow transplantation could be applied to patients

155 AB vector system when combined together with bone marrow transplantation could quickly knock down c-k

156 Bone marrow transplantation demonstrated that Gabpalpha

157 In one patient who previously received bone marrow transplantation, different minor allele freq

158 After bone marrow transplantation, donor-derived immune cells

159 Bone marrow transplantation experiments confirmed that t

160 Bone marrow transplantation experiments demonstrated tha

161 Through bone marrow transplantation experiments in a transgenic

162 Bone marrow transplantation experiments indicated that A

163 Bone marrow transplantation experiments isolated the att

164 Bone marrow transplantation experiments revealed that en

165 Bone marrow transplantation experiments revealed that MA

166 Bone marrow transplantation experiments revealed that no

167 Furthermore, bone marrow transplantation experiments revealed that T

168 Bone marrow transplantation experiments revealed that th

169 Bone marrow transplantation experiments revealed that th

170 Bone marrow transplantation experiments revealed that TL

171 Similarly, adoptive transfer and bone marrow transplantation experiments showed different

172 Bone marrow transplantation experiments showed that the

173 Bone marrow transplantation experiments suggest that REG

174 Bone marrow transplantation experiments were performed t

175 Lung transcriptomics, bone marrow transplantation experiments, and analysis of

176 In bone marrow transplantation experiments, the development

177 Bone marrow transplantation failed to rescue outgrowth.

178 Murine-competitive bone marrow transplantation followed by treatment with A

179 safely replaced with hydroxyurea therapy or bone marrow transplantation for a cohort of children wit

180 opical timolol for infantile hemangiomas and bone marrow transplantation for dystrophic epidermolysis

181 visable before commencing clinical trials of bone marrow transplantation for epidermolysis bullosa si

182 Specific tolerance after combined kidney and bone marrow transplantation for multiple myeloma with en

183 ylaxis for both acute and chronic GVHD after bone marrow transplantation from HLA-matched donors.

184 tantly, in vivo thrombosis experiments after bone marrow transplantation from platelet-specific ERK5

185 Engraftment was faster after bone marrow transplantation from siblings and was associ

186 ences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors.

187 cardiac hypertrophy or dysfunction, whereas bone marrow transplantation from wild-type mice into mic

188 after recipients were given T cell-depleted bone marrow transplantations from major histocompatibili

189 Neither irradiation nor bone marrow transplantation had any effect on the 40% di

190 r-deficient, LDLr(-/-) chimeras, obtained by bone marrow transplantation, had smaller but, paradoxica

191 atched, or HLA-haploidentical, related donor bone marrow transplantation (haploBMT) has seen a reviva

192 Allogeneic bone marrow transplantation has been attempted in severe

193 apy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve ou

194 tment or cure for epidermolysis bullosa, but bone marrow transplantation has been suggested to improv

195 In the most severe cases allogeneic bone marrow transplantation has been used, yet because o

196 Bone marrow transplantation has resulted in life-saving

197 We also found that after bone marrow transplantation, host macrophages retained t

198 ower after UCB than after 8/8 allele-matched bone-marrow transplantation (HR 0.63, 0.44-0.90; p=0.01)

199 ents (HR 1.62, 95% CI 1.18-2.23; p=0.003) or bone-marrow transplantation (HR 1.69, 95% CI 1.19-2.39;

200 regimen to improve the outcome of unrelated bone marrow transplantation in Fanconi anemia (FA).

201 Finally, WT bone marrow transplantation in IL10KO mice inhibited tra

202 , which expanded in the spleen subsequent to bone marrow transplantation in mice.

203 rvival and other outcomes for UCB, PBPC, and bone marrow transplantation in patients aged 16 years or

204 use of high-dose chemotherapy and autologous bone marrow transplantation in patients with malignant d

205 Reciprocal bone marrow transplantation in sublethally irradiated mi

206 lfan-based chemotherapy regimen was used for bone marrow transplantation in wild-type mice before sub

207 uential exposure to chemotherapy, and serial bone marrow transplantation increased senescence in anim

208 e marrow cells and increases chimerism after bone marrow transplantation, indicating that Scl is also

209 ditional Stat3 knockout strain and performed bone marrow transplantations into lethally irradiated re

210 Allogeneic bone marrow transplantation is an effective treatment fo

211 Bone marrow transplantation is associated with a high ri

212 Bone marrow transplantation is currently the only curati

213 Bone marrow transplantation is the only curative therapy

214 Allogeneic bone marrow transplantation is under investigation for a

215 Bone-marrow transplantation is an effective cell therapy

216 tress, such as during anticancer therapy and bone marrow transplantation, is of clinical significance

217 Following bone marrow transplantation, mice were fed a high-fat di

218 this devastating disorder, and suggest that bone marrow transplantation might offer a feasible thera

219 In a murine bone marrow transplantation model, the coexpression of S

220 In a murine bone marrow transplantation model, the differential migr

221 s demonstrate efficacy in a JAK2V617F murine bone marrow transplantation model, the effects of JAK2 i

222 In a bone marrow transplantation model, the interaction betwe

223 thal myeloproliferative disorder in a murine bone marrow transplantation model.

224 ry human hematopoietic cells and in a murine bone marrow-transplantation model using lentivirally med

225 against this recalcitrant mutant in a murine bone-marrow transplantation model.

226 sed for GVHD prevention in murine allogeneic bone marrow transplantation models.

227 ed, parent-->F1, and miHAg-mismatched murine bone marrow transplantation models.

228 The role of combination therapies and bone marrow transplantation needs further investigation.

229 Bone marrow transplantation not only rescued hematopoies

230 85beta resulted in increased mast cells, and bone marrow transplantation of cells overexpressing p85b

231 atopoietic cell intrinsic activity of Itfg2, bone marrow transplantation of Itfg2-deficient cells was

232 Bone marrow transplantation of SENP1 KO fetal liver cell

233 Lastly, with restorative bone marrow transplantation of Tie2-GFP-labeled BMDC pop

234 targets to enhance platelet production after bone marrow transplantation or chemotherapy.

235 othyroidism in contrast to mice treated with bone marrow transplantation or gene therapy.

236 This protection can be transferred by bone marrow transplantation or platelet transfusion.

237 mprovements in conventional chemotherapy and bone marrow transplantation, overall survival remains po

238 with wild-type (WT) recipients of allogeneic bone marrow transplantation, P-selectin(-/-) recipients

239 Bone marrow transplantation partially attenuated hypokin

240 In addition, 9 months after bone marrow transplantation, patient 1 had Hashimoto thy

241 We developed a nonmyeloablative bone marrow transplantation platform using related, incl

242 ation allowed the patient to be referred for bone marrow transplantation, potentially curative for hi

243 This diagnosis affects the choice of bone marrow transplantation preparative regimen and can

244 By using a reciprocal bone marrow transplantation procedure between wild-type

245 nockdown in macrophages using transgenic and bone marrow transplantation procedures to blunt HFD-indu

246 us cells might interfere with the outcome of bone marrow transplantation, protocols usually include c

247 marrow-derived cells migrate to the skin of bone marrow transplantation recipient mice, but these ce

248 lly lose function following transfer to male bone marrow transplantation recipients, we have explored

249 ficant morbidity and mortality in cancer and bone marrow transplantation recipients.

250 Bone marrow transplantation recreated the haemopoietic p

251 Bone marrow transplantation remains the only cure for PN

252 Bone marrow transplantation reproduced these phenotypic

253 Bone marrow transplantation rescued the anemia phenotype

254 Studies on mice after bone marrow transplantation revealed that CD73 present o

255 Bone marrow transplantations revealed a strong cell intr

256 er intracranial injections of AAV2/5-PPT1 or bone marrow transplantation, separately as well as in co

257 t3-deficient mice, was less prominent in the bone marrow transplantation setting, possibly by limitin

258 Bone marrow transplantations show that the platelet phen

259 Bone marrow transplantation showed that the defect in VD

260 a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to tra

261 iciency did not affect immune responses, and bone marrow transplantation studies also indicated that

262 Reciprocal bone marrow transplantation studies and myeloid cell-spe

263 Bone marrow transplantation studies demonstrated that lo

264 Multiple bone marrow transplantation studies demonstrated that th

265 Last, we performed bone marrow transplantation studies in Rag-5xfAD mice, r

266 Importantly, bone marrow transplantation studies revealed an essentia

267 Bone marrow transplantation studies show that expression

268 Bone marrow transplantation studies showed that hPepT1 e

269 Finally, bone marrow transplantation studies were performed to de

270 colony-forming/replating assays and in vivo bone marrow transplantation studies, we show that forced

271 s required on cells that are not replaced by bone marrow transplantation, such as vascular endothelia

272 findings, which may be relevant to clinical bone marrow transplantation, suggest that neither exposu

273 e development in vivo, and after competitive bone marrow transplantation, there was a nearly complete

274 LL-fusion-mediated leukemogenesis in primary bone marrow transplantation through suppressing Hoxa9/Me

275 patients needing LT should be considered for bone marrow transplantation to achieve cure.

276 Some women suffering from leukemia require bone marrow transplantation to be cured.

277 In addition, we used bone marrow transplantation to generate sickle mice defi

278 approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to devel

279 Bone marrow transplantation to replace IL-10 KO marrow w

280 der, and patients are treated primarily with bone marrow transplantation to restore hematopoietic fun

281 Furthermore, we used bone marrow transplantation to reveal that CAMK2gamma in

282 ne therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathog

283 alcification of C57BL/6 LDLr(-/-) mice using bone marrow transplantation to trace ROSA26-LacZ-labeled

284 during a period of immunocompromise after a bone marrow transplantation to treat hypodiploid leukemi

285 ws efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and par

286 Nine intensive care and bone marrow transplantation units in six hospitals were

287 il to reconstitute following irradiation and bone marrow transplantation unless the mice also receive

288 g lung allograft tolerance with tandem donor bone marrow transplantation using a short-duration nonmy

289 Bone marrow transplantation using wild-type C57BL/6 dono

290 re model was more equivocal, so experimental bone marrow transplantation was used to examine hematopo

291 Using bone marrow transplantation, we determined that hematopo

292 Using bone marrow transplantation, we present evidence that th

293 Through the use of mouse tumor models and bone marrow transplantations, we show that platelet-deri

294 me polymerase chain reaction, and reciprocal bone marrow transplantation were used to evaluate the ef

295 platelet P-selectin expression generated by bone marrow transplantation were used.

296 ppression is most profound during GVHD after bone marrow transplantation where an inflammatory cytoki

297 y from myeloablative challenge and following bone marrow transplantation, whereas BCL-XL was dispensa

298 sease (GVHD) is a complication of allogeneic bone marrow transplantation whereby transplanted naive a

299 iency virus or AIDS, or prior solid organ or bone marrow transplantation with receipt of chronic immu

300 dy of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of s